PD-L2驱动对EGFR-TKIs的耐药性:瘤免疫环境的动态变化和向治疗
Simeng Wang1,2, Dongliang Su1,2, Han Chen1,2
1Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
Cell death and differentiation
|May 30, 2024
概括
在EGFR突变瘤中对EGFR-TKI获得的耐药性是由PD-L2驱动的,PD-L2抑制CD8+T细胞. 一种天然的抑制剂,脱酸,与EGFR-TKI结合,通过恢复T细胞介导的亡,协同扭转这种抵抗.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在EGFR突变瘤中缺乏EGFR-TKI耐药性的有效治疗方法.
- 了解耐药机制对于开发向疗法至关重要.
- 瘤免疫微环境的动态被认为是抵抗的外部因素.
研究的目的:
- 研究瘤免疫环境在EGFR-TKI耐药性中的作用.
- 找出抗药性发展的机制.
- 发现新的治疗策略来克服EGFR-TKI耐药性.
主要方法:
- 使用EGFR突变细胞系和携带神经性瘤的小鼠模型.
- 分析了瘤免疫环境中的动态变化.
- 研究了PD-L2表达的作用及其与CD8+T细胞的相互作用.
- 采用单细胞测序和体外/体内实验.
- 评估了单独和与EGFR-TKIs结合使用的PD-L2抑制剂非酸盐的疗效.
主要成果:
- 对EGFR-TKIs获得的耐药性与异常的PD-L2表达有关,将瘤免疫环境转移到免疫抑制状态.
- PD-L2 抑制 CD8+ T 细胞增殖和细胞毒性功能 (granzyme B, perforin),减少 T 细胞介导的亡并促进瘤免疫逃生.
- 非乙酸选择性地阻断PD-L2 / PD-1相互作用,逆转免疫抑制瘤微环境.
- 非酸盐和EGFR-TKIs的联合疗法协同克服了依赖CD8+ T细胞介导的亡的抗性.
结论:
- 在EGFR突变瘤中,PD-L2/PD-1信号通路是EGFR-TKI耐药性的关键驱动因素.
- 异常的PD-L2表达创造了一个免疫抑制的瘤微环境,损害了抗瘤免疫力.
- 作为天然PD-L2抑制剂的无酸显示出作为治疗剂的潜力,可以逆转EGFR-TKI耐药性,特别是与EGFR-TKI结合使用.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.6K
相关概念视频
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:27Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K